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MicroRNA-222 reprogrammed cancer-associated fibroblasts
enhance growth and metastasis of breast cancer
Annesha Chatterjee1, Samir Jana1, Soumya Chatterjee1, Laura M. Wastall2, Gunjan Mandal1, Nelofar Nargis1, Himansu Roy3,
Thomas A. Hughes 4 and Arindam Bhattacharyya 1
BACKGROUND: Cancer-associated fibroblasts (CAFs) are known to impact on tumour behaviour, but the mechanisms controlling
this are poorly understood.
METHODS: Breast normal fibroblasts (NFs) or CAFs were isolated from cancers by laser microdissection or were cultured. Fibroblasts
were transfected to manipulate miR-222 or Lamin B receptor (LBR). The fibroblast-conditioned medium was collected and used to
treat epithelial BC lines MDA-MB-231 and MDA-MB-157. Migration, invasion, proliferation or senescence was assessed using
transwell, MTT or X-gal assays, respectively.
RESULTS: MiR-222 was upregulated in CAFs as compared with NFs. Ectopic miR-222 expression in NFs induced CAF-like expression
profiles, while miR-222 knockdown in CAFs inhibited CAF phenotypes. LBR was identified as a direct miR-222 target, and was
functionally relevant since LBR knockdown phenocopied miR-222 overexpression and LBR overexpression phenocopied miR-222
knockdown. MiR-222 overexpression, or LBR knockdown, was sufficient to induce NFs to show the CAF characteristics of enhanced
migration, invasion and senescence, and furthermore, the conditioned medium from these fibroblasts induced increased BC cell
migration and invasion. The reverse manipulations in CAFs inhibited these behaviours in fibroblasts, and inhibited paracrine
influences on BC cells.
CONCLUSION: MiR-222/LBR have key roles in controlling pro-progression influences of CAFs in BC. This pathway may present
therapeutic opportunities to inhibit CAF-induced cancer progression.
British Journal of Cancer (2019) 121:679–689; https://doi.org/10.1038/s41416-019-0566-7
BACKGROUND
Breast cancer (BC) is the leading cause of cancer death worldwide
among women,1 and nearly 2.3 million females are newly
diagnosed annually.2 Although there are initial responses to
treatment, many cancers relapse and distant metastases occur in
nearly one-third of woman; these are typically fatal.3 The biology
behind BC metastases still remains undetermined. Therefore,
understanding molecular determinants of metastasis is crucial for
finding new therapeutic strategies. The tumour microenvironment
consists of immune cells, blood vessels, endothelial cells,
fibroblasts and extracellular matrix.4 This microenvironment plays
key roles in disease outcome by inducing tumour cell proliferation
and aggressiveness.5,6 Cancer-associated fibroblasts (CAFs), an
activated form of tissue-resident fibroblasts present within breast
cancers, comprise a major component of the tumour microenvir-
onment,7 characterised most commonly by expression of α-
smooth muscle actin.8 CAFs can induce cancer progression9 and
metastasis10 by secreting various cytokines, chemokines and
growth factors (e.g., VEGF, FGF2, TGFβ, CXCL12, IL6 and IL8)11,12
and by modulating the extracellular matrix (ECM) that facilitates
tumour cell migration and invasion.13,14 CAFs also modulate
immune cell function to create an immune-suppressive environ-
ment during cancer progression.15 The process of transformation
of CAFs from resident normal fibroblasts is achieved by several
growth factors,16–18 however, the mechanisms of transformation
have not yet been fully explored and may represent attractive
targets for therapeutic intervention; interestingly, once trans-
formed into CAFs, the CAF phenotype has been regarded as
stable, probably though maintenance of epigenetic changes.19
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate
gene expression by binding to the 3′untranslated regions (3′UTRs)
of target genes, leading to post-transcriptional downregulation.20
MiRNAs can be oncogenic or act as tumour suppressors,
depending upon the specific genes that they regulate.21,22
Dysregulation of miRNAs within the fibroblast component of
breast cancer has been reported, and is therefore implicated in
induction or maintenance of the CAF phenotype. For example,
differential expression between breast CAFs and normal fibro-
blasts has been reported for many miRNAs, including miR-221,
miR-31, miR-205, miR-200b, miR-200c, miR-107, miR-30b, the let-7
family and miR-26b,23,24 although there is relatively little
consistency between reports. Far fewer miRNAs have been shown
experimentally to have functional impacts on the breast CAF
phenotype, or most interestingly indirectly on cancer cell
behaviour; examples include miR-26b,24 let-7b,25 miR-200 family26
and miR-29b.27 Although some of these studies have indicated
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functional roles for specific miRNAs within CAFs, very few studies
have directly investigated miRNA roles on the transformation and
maintenance of CAF phenotypes and on how this impacts on
cancer behaviour, therefore how miRNAs in CAFs are involved in
cancer progression remains poorly understood. Here, we have
focussed on miR-222 as a candidate regulator of CAF phenotypes
and cancer behaviour. MiR-222 has previously been reported as an
oncogenic miRNA in various cancers, including BC,28–32 function-
ing within the cancer cells themselves, as opposed to stromal cells.
Furthermore, it has been shown that upregulation of miR-222
induced growth of cancer cells by targeting p27/kip1,32 as well as
chemoresistance by targeting PTEN/Akt.33 Interestingly, in the
context of our study on function in fibroblasts, levels of miR-222
positively correlated with fibroblast viability in hypertrophic scar
tissues,34 while miR-222 has been shown to induce replicative
senescence in human lung fibroblasts.35 However, to date, no
studies have been published on roles of miR-222 in CAFs.
Therefore, the above observations suggest the importance of
miR-222 as a post-transcriptional modifier, playing functional roles
in BC progression. However, it is unclear whether expression of
miR-222 is only tumour cell specific or the other cells also express
miR-222 in tumour microenvironment. As miR-222 is an important
oncogenic factor in breast cancer, we wanted to unveil whether
CAFs also expressed miR-222 to influence disease progression.
MATERIALS AND METHODS
Reagents
Foetal bovine serum (FBS), DMEM and antibiotic/antimycotic
(100X; 10,000 units/mL penicillin, 10,000 µg/mL streptomycin,
25 µg/mL amphotericin B) were purchased from ThermoFisher
(MA, USA). Antibodies for α-smooth muscle actin (ab5694), LBR
(ab32535) and β-actin (ab8227) were purchased from Abcam (MA,
USA), and for vimentin (#5741S) and Slug (#9585S) from Cell
Signaling Technology (MA, USA). Secondary anti-rabbit antibody
was purchased from Bangalore Genei (Bangalore, India). Alexa-
Fluor 488-conjugated anti-rabbit and TRITC-conjugated anti-rabbit
antibodies were purchased from ThermoFisher (MA, USA). MiR-
222-3p mimics (#MSY0000279) and inhibitors (#MIN0000279),
miScript inhibitor negative control (#1027271), siLBR
(#SI00035798) and AllStars negative control siRNA (#1027280)
were purchased from Qiagen (Hilden, Germany). Lipofectamine
3000 was purchased from ThermoFisher (MA, USA). β-
galactosidase assay kit was purchased from Cell Signaling
Technology (MA, USA). KpnI, XbaI, PmeI, NotI and T4 DNA ligase
were purchased from New England Biolabs (MA, USA).
Ethical issues and cell culture
Ethical approval for collection and use of human tissue was
obtained from the Leeds East REC (references 06/Q1206/180, 09/
H1306/108), and also from the Ethical Committee, Medical
College, Kolkata, references MC/KOL/IEC/NON-SPON/102/09-
2015. Fresh samples of surgically removed breast cancer samples
were minced, digested with collagenase IV from HiMedia
Laboratories Pvt. Ltd (Mumbai, India) and plated (collagenase I
coated) to derive primary breast CAFs (from within tumour
masses) and NFs (from > 1 cm outside tumour margins). Breast
cancer cell lines MDA-MB-231 and MDA-MB-157 were obtained
from the ATCC (VA, USA). The NF and CAF fibroblast lines were
derived from breast cancer samples and immortalised using
lentiviral transduction of hTERT, as previously described.24 All cell
lines were cultured in the DMEM with 10% FBS and 1% antibiotics/
antimycotics in a humid atmosphere incubator with 5% CO2 at
37 °C. NFs were transfected with scrambled siRNA negative control
(NC), siLBR, miR-222 mimic or mimic control using Lipofectamine
3000 (ThermoFisher; MA, USA) according to the manufacturer’s
instruction. Similarly, CAFs were transfected with scramble
negative control, miR-222 inhibitor, pCDNA or pCDNA-LBR.
Seventy-two hours after transfection, cells were harvested for
western blotting, qRT-PCR analyses, senescence studies or
migration/invasion studies. To collect NF and CAF conditioned
medium, cells were seeded into six-well plates at 1.5 × 105 cells/
well. As previously described, cells were transfected as appropriate
for 24 h, then medium was replaced with fresh DMEM. After 48
and 72 h of incubation, the medium was collected and centrifuged
at 150 g for 5 min, and then the supernatant was collected.
RNA isolation and qPCR
For LMD samples, the total RNA was extracted from using
RecoverAll Total Nucleic Acid Isolation Kit for FFPE (ThermoFisher,
MA, USA) following the manufacturer’s protocols, or the mirVa-
naTM miRNA Isolation Kit (ThermoFisher, MA, USA). RNA was
reverse-transcribed for miR-222 using the TaqMan MicroRNA RT kit
(ThermoFisher, MA, USA), and the resulting first strand was
amplified using specific Taqman miRNA assay primers (Thermo-
Fisher, MA, USA). The PCRs were performed by StepOne plus
detection system (ThermoFisher, MA, USA), and amplification data
were normalised using RNU6 expression. Relative expression levels
were calculated using the 2–ΔΔCt method. For cultured primary
fibroblasts (in Fig. 1b), RNA was isolated from a 90-mm dish of
cultured cells using TRIzol (ThermoFisher, MA, USA), according to
the manufacturer's instruction and RNA quantified by MULTI-
SCANGO (ThermoFisher, MA, USA). For miRNA expression status
and gene expression status, first strand cDNA and cDNA were
synthesised with miScript RT-II kit (Qiagen, Hilden, Germany) and
Superscript III (ThermoFisher, MA, USA), respectively. MiR-222
expression was analysed using PCR starter kits (Qiagen, Hilden,
Germany); U6 was used as an endogenous control. Quantitative
RT-PCR was performed using the Power SYBR Green Master Mix
(ThermoFisher, MA, USA) on StepOne detection system (Thermo-
Fisher, MA, USA). Expression was normalised to the house-keeping
gene 18S.
Protein extraction and western blots
Cells were washed with PBS and lysed in RIPA lysis buffer System
(lysis buffer pH 7.4, 200 mM PMSF, protease inhibitor cocktail,
100mM sodium orthovanadate) (Santa Cruz-sc24948). The lysates
were centrifuged at 12700 g for 20 min at 4 ˚C. Protein concentra-
tions were determined using BCA Protein Assay Kit (ThermoFisher,
MA, USA). Total protein was separated by SDS-PAGE (12% gel)
then transferred to the PVDF membranes (Millipore) and blocked
with 5% skimmed milk. The membrane was then incubated
overnight with primary antibodies. Protein bands were detected
by incubation with horseradish peroxidase (HRP)-conjugated
antibodies (Bangalore Genei, Bangalore, India). Bands were
visualised using ECL.
Histology, laser capture microdissection (LMD) and
immunohistochemistry (IHC)
LMD was carried out on the Zeiss PALM Laser Capture
Microdissection Microscope exactly as described previously.24 In
brief, archival FFPE cancer blocks and matched normal blocks
were obtained and sectioned at 10 μm onto Membrane Slides NF
1.0 PEN (Zeiss, Oberkochen, Germany). A guide section was
stained with haematoxylin and eosin and reviewed by a
histopathologist (LMW) to identify areas of fibroblasts with very
few admixed inflammatory cells, epithelial cells or necrosis. The
equivalent areas were then identified on other sections, and these
were collected with the laser into lids of AdhesiveCap500 opaque
PCR Tubes (Zeiss, Oberkochen, Germany) by laser pressure
catapulting (LPC). The microscope settings used for LCM were
cut energy 71, focus 65, LPC energy 100, focus 65 at ×100
magnification. Areas dissected from each case varied between 5.2
and 27.4×106 μm2 depending on fibroblast density. For IHC, FFPE
human breast cancer resection tissue was available; cancerous and
non-cancerous breast tissue were immunostained for α-SMA and
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LBR. The signal was amplified and visualised with 3, 3-
diaminobenzidine (DAB) chromogen, followed by counterstaining
with haematoxylin.
Luciferase reporter assays
The potential miR-222 binding sequence from the LBR gene (WT
LBR) and three nucleotide-mutated LBR (MUT LBR) (Fig. 2a) were
cloned into pMiRGLO (Promega, WI, USA) under restriction sites
PmeI and XbaI (primers listed in Table S1). Luciferase activities
were measured 48 h after transfection using Dual-Luciferase
Reporter Assays (Promega, WI, USA).
Cell proliferation assays
NFs and CAFs were seeded in 96-well plates at 1 × 104 cells/well
and transfected the following day. Cell proliferation was
monitored after 72 h by MTT (HiMedia Laboratories, Mumbai,
India). In total, 10 µl of MTT solution (10 mg/ml) in 100 µl of DMEM
media was added per well. After 4 h of incubation, formazan
complexes were dissolved in 100 µl of DMSO, and signals were
measured using MULTISCANGO plate reader (ThermoFisher, MA,
USA). To evaluate the effects of conditioned media, MDA-MB-231
and MDA-MB-157 were seeded in 96-well plates at 2 × 104 cells/
well. Twenty-four hours after seeding, condition media was
applied. MTT assays were performed at 48 h as above.
Cell migration and invasion assays
Cell migration and invasion ability were determined by Corning
transwell insert chambers (8-µm pores; Corning, MA, USA) and
Matrigel (Sigma Aldrich, MO, USA) coated in a transwell chamber
for invasion analysis. Conditional media from different treatment
conditions were used in lower chambers for migration and
invasion study. The cells were prior treated with conditional media
for 48 h. In total, 1 × 105 cells of MDA-MB-231 or MDA-MB-157
were added into chambers and incubated for 28 h at 37 °C. Cells
that had migrated or invaded were fixed with 100% methanol,
stained with 0.5% crystal violet, imaged and counted manually.
Senescence-associated beta-galactosidase (SA-β-gal) assays
SA-β-gal activity was detected by β-gal staining kit (Cell Signaling
Technologies) according to the manufacturer's instructions. Cells
containing blue stain were counted manually as positive
senescent cells, and images were taken under phase contrast.
Cell immunostaining and confocal microscopy
NFs and CAFs were allowed to attach to glass coverslips overnight
at 37 ˚C. Cells were fixed in 4% paraformaldehyde (20 min) and
permeabilised with 0.1% Triton X-100 (15 min). Blocking was
performed with 5% BSA for 1 h followed by incubation with α-SMA
and vimentin primary antibodies (4 ˚C overnight). AlexaFluor 488-
conjugated and TRITC-conjugated secondary antibodies were
incubated for 1 h. Coverslips were counterstained with DAPI and
analysed on a confocal microscope (Olympus).
Cloning
For the LBR-overexpressing vector, LBR open-reading frame was
cloned within pCDNA 3.1+ vector using KpnI and XbaI restriction
sites and primers GTGGTACCACCATGCCAAGTAGGAAATTTG (for-
ward) and GCTCTAGAGCTTAGTAGATGTATGGAAATATACGG (reverse).
Statistical analyses
All data are representative of at least three independent
experiments. The results are presented as means ±SEM of at least
three independent experiments in all the figures. Differences were



















































































































































Fig. 1 MiR-222 is upregulated in breast cancer-associated fibroblasts (CAFs), and controls breast fibroblast phenotype. a MiR-222 expression
was determined by qPCR, and is shown for CAFs relative to NFs in three separate cell types. Left plot: matched pairs of normal fibroblasts (NFs)
and CAFs were isolated from breast cancer patient samples using laser microdissection of archival (fixed) tissue. The data represent technical
triplicates. Middle plot: four matched pairs of primary cultured CAFs and NFs from breast cancer patient-derived tumour samples. The data
represent technical triplicates. Right plot: immortalised breast CAF and NF cell lines. The data represent biological triplicates. b Immortalised
breast NFs (left) or CAFs (right) were transfected with miR-222 mimics or control (NC), or miR-222 inhibitor (i) or control (NC) and miR-222
expression was assessed using qPCR. Data represent biological triplicates. c Relative gene expression levels of the CAF markers, α-SMA,
Fibroblast Specific Protein (FSP), CCL2 and VEGF were assessed in immortalised CAFs as compared with immortalised NFs using qPCR. The
data represent biological triplicates. d Relative expression levels of the same CAF markers were assessed using qPCR in NFs (left) or CAFs
(right) transfected with miR-222 mimics or control (NC), or miR-222 inhibitor (i) or control (NC). The data represent biological triplicates. e NFs
or CAFs were transfected with miR-222 mimics or control (NC), or miR-222 inhibitor (i) or control (NC) and protein expression of the CAF
markers α-SMA (ACTA2) and vimentin were assessed using Western blots, along with β-actin as a loading control. ***p < 0.0005 and **p < 0.005
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RESULTS
miR-222 is upregulated in breast CAFs, and controls CAF
phenotypes
Many studies have shown that miRNAs are dysregulated in CAFs.
To investigate roles of miR-222 dysregulation in CAF biology, we
first assessed relative expression of miR-222 in 14 matched pairs of
normal fibroblasts (NFs) and cancer-associated fibroblasts (CAFs)
that have been isolated from breast cancer resection samples
using laser microdissection (LMD). We found miR-222 to be
upregulated in CAFs relative to matched NFs in 11 out of 14 cases,
representing significant upregulation overall by a mean fold of
3.63 (p < 0.04; Fig. 1a, left plot). To expand this finding, we further
assessed miR-222 expression in four matched pairs of primary
human breast NFs and CAFs cultures extracted from breast cancer
resections; we found a greater than twofold induction of miR-222
in CAFs as compared with matched NFs in all cases (Fig. 1a, middle
plot). Finally, miR-222 expression in immortalised human breast
NFs was compared with immortalised human breast CAFs; this
also showed higher expression of miR-222 in CAFs by more than
threefold (Fig. 1a, right plot). We concluded that miR-222 is more
highly expressed in CAFs than NFs in breast tissue.
To explore functional roles of miR-222 in transformation of NFs
to CAFs, we conducted a series of experiments on immortalised
human breast NFs or immortalised human breast CAFs using miR-
222 mimics to upregulate expression in NFs, or miR-222 inhibitors
to downregulate expression in CAFs. First, miR-222 expression was
assessed using qRT-PCR to confirm appropriate over- or under-
expression (Fig. 1b); miR-222 was significantly overexpressed by
more than eightfold and was knocked down to one-third of its
original level. Next, the relatively “normal” or CAF-like phenotypes
of these cell lines were characterised to establish their baselines
for subsequent analyses. Expression of a range of classical CAF
markers7,8,12 was assessed using qRT-PCR (Fig. 1c), immunofluor-

































































































































P1 P2 P3 P4 P5 P6 P7 P8
Fig. 2 Lamin B Receptor (LBR) is a direct target of miR-222 in breast fibroblasts and is downregulated in breast CAFs relative to matched NFs.
a LBR was identified as a potential miR-222 target by bioinformatics. The potential miR-222-binding site within the LBR 3′UTR is shown (WT),
along with a binding-dead mutant used experimentally (MUT). b Luciferase reporters were cloned that allow expression of luciferase
transcripts containing the wild-type or mutant LBR miR-222 3′UTR binding sites. These were transfected into NFs (left) or CAFs (right) along
with either miR-222 mimic or control (NC), or miR-222 inhibitor (i) or control (NC), and relative luciferase activity was determined. The data
represent two biological replicates. c, d NFs or CAFs were transfected as shown, and the relative expression of endogenous LBR was
determined using qPCR (c) or western blots (d). qPCR data represent three biological replicates. e Representative matched pair of normal and
breast cancer tissues was assessed for expression of LBR by immunohistochemistry (×10 and ×20 magnification). Brown staining represents
expression of the target protein, while pink is a counterstain. f Relative expression of LBR was assessed in eight pairs of primary cultured NFs
and CAFs isolated from breast cancer patient-derived tumour. The data represent technical triplicates. g Protein expression levels of LBR, and
the CAF markers α-SMA and vimentin were assessed by western blotting in three pairs of primary cultured NFs and CAFs isolated from breast
cancer patient-derived tumour samples. β-actin was used as a loading control. ***p < 0.0005, **p < 0.005, *p < 0.05
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ACTA2 (smooth muscle actin), FSP, CCL2 and VEGF were all
substantially higher in CAFs as compared with NFs (a minimum of
fivefold higher as assessed by qRT-PCR), as indicative of the CAF
phenotype. Upregulation in CAFs of ACTA2/smooth muscle actin
and vimentin was also confirmed at the protein level (Fig. S1).
Next, NFs were transfected with miR-222 mimics or control
mimics, and CAFs were transfected with miR-222 inhibitors or
control inhibitors, and miR-222′s influence on transformation of
NFs to CAFs, or on maintenance of the CAF phenotype was
examined using the same panel of CAF markers as previously.
Transfection of miR-222 mimics in NFs resulted in significant
upregulation of all the CAF markers (qRT-PCR, Fig. 1d, left plot;
western blots, Fig. 1e). Furthermore, downregulation of miR-222 in
CAFs using miR-222 inhibitors significantly downregulated expres-
sion of the CAF markers, with the notable and surprising exception
of CCL2 (qRT-PCR, Fig. 1d, right plot; western blots, Fig. 1e). We
concluded that miR-222 levels play key roles in controlling the CAF
phenotype in breast fibroblasts.
LBR is a direct target of miR-222
To investigate potential mechanisms by which miR-222 plays roles
in breast fibroblast biology, bioinformatics tools were used to
predict potential target genes of miR-222. We analysed the best
possible miR-222 seed matches using miRanda, TargetScan and
miRDB software. Eleven predicted target genes were chosen for
further analysis based on the target scores, containing seed
matches for miR-222. On analysis of expression by qRT-PCR in NFs
and paired CAFs from patient samples three of these genes, RECK,
THOP1 and LBR, demonstrated differential expression in the
predicted direction. LBR showed the most substantial and
consistent dysregulated result in NFs and CAFs, and therefore
LBR was prioritised for subsequent analyses. The potential miR-222
binding site within the LBR 3′UTR is depicted in Fig. 2a. We
performed a number of different assays to assess whether LBR is a
true direct target of miR-222 within breast fibroblasts. First,
luciferase reporter constructs containing either the wild-type miR-
222 binding site from the LBR 3′UTR or a mutated (non-binding)
version of the site (Fig. 2a) were cloned. Reporters were co-
transfected with miR-222 mimics and inhibitors, or appropriate
controls, in NFs and CAFs respectively, and luciferase assays were
performed. MiR-222 mimics significantly inhibited the activity of
the luciferase reporter containing the wild-type LBR site, while the
mutated site was insensitive to miR-222 overexpression in NFs
(Fig. 2b, left plot), whereas miR-222 inhibitors significantly
increased the activity of the wild-type reporter, while the mutated
reporter was again insensitive in CAFs (Fig. 2b, right plot). Next,
endogenous LBR expression was assessed in NFs after transfection
to overexpress miR-222, and in CAFs after transfection with miR-
222 inhibitors (Fig. 2c, d). LBR expression was downregulated by
miR-222 overexpression and upregulated by miR-222 inhibition at
the level of both transcript (Fig. 2c) and protein (Fig. 2d), findings
that were in accordance with it being downstream of miR-222
function. We concluded that LBR is a direct target of miR-222 in
breast fibroblasts, via a canonical miR-222 binding site within the
LBR 3′UTR.
Downregulation of LBR induces a CAF-like phenotype
Our next aim was to determine whether LBR downregulation is
involved in determining the breast CAF phenotype, since we have
already determined that CAFs overexpress miR-222 and that this
can downregulate LBR. In one approach, we examined whether
breast normal stroma or tumour stroma exhibit differential
expression of LBR using immunohistochemistry. LBR expression
(Fig. 2e) was relatively reduced in tumour stroma, in contrast to
ACTA2 (smooth muscle actin) (Fig. S2), which was relatively high in
tumour stroma. In addition, qRT-PCR was performed on eight
matched pairs of primary NF and CAF cultures. LBR expression was
significantly reduced by a mean of 4.3-fold in CAFs compared with
the NFs (p < 0.01), in contrast to expression of the CAF markers
ACTA2 and vimentin, which were upregulated in CAFs as expected
and indicative of the CAF phenotype (Fig. 2f, g).
We next assessed whether LBR downregulation was sufficient
for transformation of NFs to CAFs, and conversely whether LBR
overexpression would reduce CAF features. We transfected
immortalised breast NFs with siRNA targeted against LBR or with
an appropriate non-targeting control, and also transfected
immortalised breast CAFs with plasmids to allow overexpression
of LBR, or with appropriate control plasmids. The efficacy of
knockdown and overexpression was confirmed using qRT-PCR
(Fig. 3a) and western blots (Fig. 3b); knockdown was to ~30% of
the original levels, while overexpression was by more than
ninefold. Next, we assessed expression of our panel of CAF
markers in these cells after knockdown or overexpression of LBR
using qRT-PCR or western blots as previously. Reduction of LBR
expression in NFs, and increased expression of LBR in CAFs,
significantly increased and decreased, respectively, the expression
of all the CAF markers (Fig. 3c–e). We concluded that LBR is a key
regulator of the breast CAF phenotype, and that knockdown of
LBR alone is sufficient to transform NFs into cells that resemble
CAFs.
MiR-222 and LBR regulate migration, invasion and senescence in
breast fibroblasts
Since it has been previously demonstrated that CAFs are
characterised by higher cell motility than their adjacent NFs,36
we also investigated whether miR-222 overexpression or siRNA-
mediated knockdown of LBR would induce increased NF
migration or invasion, and conversely whether miR-222 inhibition
or LBR overexpression would reduce CAF migration or invasion.
Immortalised breast NFs or CAFs were transfected as previously
with miR-222 mimics or inhibitors, respectively, or with siRNA
targeted against LBR or overexpression of LBR, respectively. We
then performed migration or invasion assays using transwell
assays. NFs transfected with miR-222 mimics or siRNA targeting
LBR had significantly higher migration and invasion capacity
(Fig. 4a, b, left plots), whereas inhibition of miR-222 or LBR
overexpression in CAFs significantly reduced their migration and
invasion capacity (Fig. 4a, b, right plots). In order to confirm that
these apparent effects on migration and invasion did not relate to
differences in cell numbers induced by the transfections, we also
evaluated proliferation capabilities of fibroblasts after these
manipulations of miR-222 or LBR expression. We performed MTT
assays after the same transfected conditions as mentioned above;
there were no significant differences in proliferation of NFs or
CAFs after any of these treatments (Fig. S3). We concluded that
miR-222 and its target LBR have key influences on aspects of CAF-
like fibroblast behaviour, namely migration and invasion.
It was previously reported that loss of LBR is associated with
induction of cellular senescence,37 therefore, we also specifically
evaluated senescence by determining senescence-associated
β-galactosidase (SA-β-gal) activities in NFs and CAFs after
dysregulation of expression of miR-222 or LBR. We found an
increased SA-β-gal activity in NFs transfected with miR-222 mimics
or siLBR compared to controls (Fig. 4c, left plot). In addition,
inhibition of miR-222 activity or increased LBR expression in CAFs
significantly reduced SA-β-gal activity (Fig. 4c, right plot). We also
further examined features of this senescence phenotype by
determining whether it was also associated with differential
expression of other senescence markers. NFs and CAFs were
transfected as before, and qRT-PCR was used to assess expression
of MMP3, OPN, IL6 and IL8, which are upregulated in senescent
cells particularly those showing the senescence-associated secre-
tory phenotype (SASP).38,39 Expression of all four markers was
significantly upregulated in NFs transfected with miR-222 mimic or
siLBR (Fig. 4d, left plot), while expression was significantly
downregulated in CAFs transfected with miR-222 inhibitors or to
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overexpress LBR (Fig. 4d, right plot). This provided strong support
that changes in β-gal activity we had detected were indeed
associated with senescence, and that miR-222 and LBR expression
impact on senescence phenotypes in breast fibroblasts.
miR-222 and LBR in breast fibroblasts regulate proliferation,
migration and invasion of cancer cells
To better understand the exact effects of miR-222 and its action
on LBR in fibroblasts on epithelial breast cancer cell behaviour, we
assessed abilities of NFs and CAFs after manipulation of miR-222
or LBR expression to induce growth or migration/invasion of
breast cancer cells. In particular, we focused on the highly
metastatic MDA-MB-231 and the relatively less metastatic and
triple-negative MDA-MB-157 cell lines. In order to assess
influences of fibroblasts on the cancer cells, we decided to collect
conditioned medium from fibroblasts and treat cancer cells with
this. Fibroblast-conditioned medium has frequently been shown
to influence cancer cell behaviour in this context.36 NFs or CAFs
were transfected exactly as previously. Conditional medium (CM)
was collected from these cells after transfection, and was added to
cultures of epithelial breast cancer cells. First, proliferation of
epithelial cells was assessed using MTT assays after treatment with
CM (Fig. 5a, b). In both epithelial cell lines, CM from control NFs
caused a marginal, but not significant, reduction in proliferation,
while CM from control CAFs caused a marked and significant
increase in proliferation when compared with cells without CM
(p < 0.005), as has been reported previously.36 More interestingly,
overexpression of miR-222 in NFs and knockdown of miR-222 in
CAFs significantly altered the activity of these CMs on both
epithelial cell lines; miR-222 overexpression in NFs produced CM
that had similar growth inducing effects to that from control CAFs,
while knockdown of miR-222 in CAFs reduced this growth
stimulation (Fig. 5a). Changes in LBR expression within NFs and
CAFs also had similar significant effects, with LBR knockdown
allowing CM from NFs to induce relative growth increases, while
overexpression of LBR in CAFs reduced the growth stimulatory
effect of CAF CM (Fig. 5b). We concluded that upregulation of miR-
222 and downregulation of LBR were both necessary and
sufficient for CAF function with respect to inducing proliferation
of breast cancer cells. Next, we investigated the influences of
these CMs on the motility of BC cells. BC cells also responded
dramatically and significantly to these CMs in terms of migration
and invasion capacities. CM from NFs had little influence on
migration, while CM from CAFs significant and consistently
induced migration (Fig. 5c, e) and invasion (Fig. 5d, f) in both
epithelial cell lines. Overexpression of miR-222 or knockdown of
LBR in NFs led to enhanced migration in the epithelial lines.
Knockdown of miR-222 or overexpression of LBR in CAFs led to
reduced migration in the epithelial lines. Exactly the same result
was evident in terms of invasion, with miR-222 and LBR having a
key influence on abilities of NFs or CAFs to induce invasion in both
epithelial cell lines (Fig. 5c–f). To further clarify that differences in
migration/invasion of the breast cancer epithelial cells treated
with CM did not solely relate to changes in proliferation rate, we
additionally performed an experiment assessing proliferation in
the cells treated exactly as for the migration/invasion assay
(Fig. S4), which involves an earlier time point than that used for
Fig. 5a, b. There were no significant differences in almost all
combinations, supporting the conclusion that true differences in
migration/invasion were seen. An exception is MDA-MB-157 cells
treated with CAF CM, in which a significant reduction in
proliferation was seen with CM after miR-222 knockdown and
LBR overexpression; however, this change in proliferation was only
up to 20% (Fig. S4), whereas decreases in migration/invasion were
up to 50% (Fig. 5e, f), indicating that—again—true influences on
migration/invasion were seen.
Finally, to determine whether the fibroblasts were influencing
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Fig. 3 LBR regulates the NF vs CAF breast fibroblast phenotype. a, b Immortalised breast NFs (left) or CAFs (right) were transfected with siRNA
targeting LBR (siLBR) or control (NC), or plasmid to allow overexpression of LBR (LBR OE) or control plasmid (pCDNA), and LBR expression was
assessed using qPCR (a) or western blots (b). qPCR data represent biological triplicates, while β-actin represents a loading control for the
western analysis. c–e Immortalised breast NFs (c, e) or CAFs (d, e) were transfected as shown, and the relative expression levels of the CAF
marker genes α-SMA, fibroblast-specific protein (FSP), CCL2 and VEGF were determined by qPCR (c, d), or of α-SMA and vimentin by western
blot (e). qPCR data represent biological triplicates, while β-actin represents a loading control for the western analysis. ***p < 0.0005 and
**p < 0.005
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epithelial to mesenchymal transition (EMT) pathways, we analysed
expression of EMT markers slug and vimentin in the BC cells after
culture with the same CMs, using both qRT-PCR and western blots
(Fig. 6). CM from NFs had little influence on slug or vimentin
expression at either transcript or protein level, while CM from CAFs
induced up to a sixfold increase in expression. Manipulation of
miR-222 or LBR expression in the fibroblasts consistently and
significantly altered slug and vimentin expression in accordance
with the changes in migration and invasion, with greater slug and
vimentin expression in cells induced to migrate/invade more by
miR-222 mimics or LBR siRNA in NFs, and reduced slug and
vimentin expression in cells induced to migrate/invade less by
miR-222 inhibition or LBR overexpression in CAFs. We concluded
that miR-222 and, downstream of this, LBR have key influences on
abilities of breast fibroblasts to control critical cancer-related
behaviours of breast epithelial cancer cells, including proliferation,
migration, invasion and EMT.
DISCUSSION
Increasing evidence supports the proposal that miRNA dysregula-
tion within CAFs modulates function of the tumour microenviron-
ment. However, it is worth highlighting that most studies have
emphasised investigation of miRNA roles within the tumour cells
themselves, therefore it remains the case that relatively little is
known about roles of miRNAs in the tumour microenvironment. In
this study, we have focussed on roles of miR-222 within
fibroblasts.
We initially compared the miR-222 expression difference
between CAFs and adjacent NFs in breast cancer tissue samples.
Our study demonstrated that miR-222 was significantly upregu-
lated in CAFs. Although others have made similar comparisons for
multiple miRNAs in this context,23,24,26,40 miR-222 has not
previously been identified as differentially expressed. This may
be because studies have not always effectively purified only the
fibroblasts for their analyses, as we have by LMD, or may be
because miR-222 was not always included in the analyses. Next,
we identified that miR-222 targets Lamin B receptor (LBR)
expression in the CAFs. Various targets of miR-222 have been
published previously, but LBR is a novel target on which we
focused since we were able to confirm its downregulation in CAFs
in accordance with negative regulation by the upregulated miR-
222. Most importantly, downregulation of LBR with siRNA
phenocopied miR-222 overexpression in functional experiments
using breast fibroblasts, strongly suggesting that LBR is a key
functionally important target of miR-222 in these cells.
In terms of cellular function, we showed that miR-222 and LBR
were both involved in defining and maintaining the breast CAF
phenotype in terms of expression patterns, and fibroblast
behaviours including migration and invasion. MiR-222 has
previously been assigned roles in promotion of cell proliferation,
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Fig. 4 MiR-222 and its downstream target LBR modulate the behaviour of breast fibroblasts. Immortalised breast NFs were transfected with
miR-222 mimic or siRNA targeting LBR (siLBR) or appropriate controls (NC), and immortalised breast CAFs were transfected with miR-222
inhibitor (i) or to overexpress LBR (LBR OE) or with appropriate controls (NC, pCDNA). a, b Migration (a) or invasion (b) of fibroblasts was
assessed using transwell assays. Representative images are shown (a, b, upper panels), along with quantified data that represent biological
triplicates (a, b, lower panels). c Expression of senescence-associated β-galactosidase was also assessed by X-gal staining and is shown as blue
green colouration (upper panels). Positive cells were quantified in data that represent biological triplicates (lower panels). d Expression of the
senescence markers MMP3 and osteopontin (OPN) and senescence-associated secretory phenotype markers IL6 and IL8 were assessed by
qPCR in NFs (left plot) and CAFs (right plot). The data represent biological triplicates. ***p < 0.0005, **p < 0.005, *p < 0.05
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Fig. 5 MiR-222 and LBR control the ability of breast fibroblasts to influence cancer cell proliferation and metastatic potential. Immortalised
breast NFs were transfected with miR-222 mimic or siRNA targeting LBR (siLBR) or appropriate controls (NC), and immortalised breast CAFs
were transfected with miR-222 inhibitor (i) or to overexpress LBR (LBR OE) or with appropriate controls (NC, pCDNA). Conditioned medium
(CM) was collected from fibroblast cultures and used to treat breast epithelial cancer lines MDA-MB-231 or MDA-MB-157. a, b Proliferation of
MDA-MB-231 or MDA-MB-157 cell lines cultured with conditioned medium (CM) from the transfected fibroblasts as labelled was determined
using MTT assay. The data represent biological triplicates. c–f Migration (c, e) or invasion (d, f) of epithelial cancer cells was assessed using
transwell assays. Representative images are shown (upper panels), along with quantified data that represent biological triplicates (lower
panels). ***p < 0.0005, **p < 0.005, *p < 0.05
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so our findings are in accordance with this, although they
represent the first observations to our knowledge in a cancer
stromal cell type. With respect to functions of LBR, a role in
senescence has previously been reported in fibroblasts37 and we
also observed a related result with manipulation of LBR expression
by siRNA, overexpression or via miR-222 all impacting on
senescence in breast fibroblasts. LBR encodes the lamin B receptor,
a 70.4-kD protein of the inner nuclear membrane,42 which is
known to interact with heterochromatin and B-type lamins.43
Other functions for the protein have been implied by observations
that ectopic LBR expression deregulates differentiation of olfactory
neurons inducing an un- or early-differentiated state.44
More excitingly, we showed that fibroblasts with differential
expression of miR-222 or LBR have potent differential influences
on behaviour of two independent breast epithelial cancer cell
lines. We demonstrated that conditioned medium from fibroblasts
that were stimulated to be more CAF-like by miR-222 over-
expression or siLBR promoted breast cancer proliferation, migra-
tion and invasion. Similarly, abilities of conditioned medium from
CAFs to promote breast cancer proliferation, migration and
invasion was inhibited by reduced miR-222 levels or by LBR
overexpression. Next, we investigated possible pathways involved
in the breast tumour motility effects. We found that the enhanced
migration and invasion were associated with increased expression
of vimentin and slug in the BC cells, suggesting involvement of
the EMT pathway. Taken together, these results suggest that miR-
222 upregulation, and subsequent LBR downregulation, within
fibroblasts in the tumour microenvironment contribute to
progression of BC, through induction of proliferation and EMT-
related motility. It is established that cancer progression is not
only dependent on tumour cells themselves but also dependent
on the tumour microenvironment45,46 and, in particular, CAFs,
which promote growth and invasion of cancer cells through
synthesis and remodelling of ECM and secreting some growth
factors.4,47 Hence, blocking CAF activity may be a key approach to
effectively control cancer metastasis. Manipulation of either miR-
222 expression or LBR function provide candidate approaches for
development of these types of anti-cancer therapies. In particular,
our data demonstrate that reduced expression of miR-222 or
overexpression of LBR in CAFs greatly reduces their ability to
promote aggressive behaviours in cancer cells, supporting the
proposal that CAF phenotypes are not fixed and could be
normalised therapeutically.
Surprisingly, our data also implicate the miR-222/LBR axis in
senescence induction in CAFs. Previous studies have indicated
that increased miR-222 or loss of LBR induces senescence,35,48 so
this is not a surprise in itself; however, it is unexpected that high
levels of senescence in CAFs would be associated with cancer cell
behaviours that promote progression, since senescence is often
regarded as a tumour-suppressor mechanism in cancer cells.49
However, more recent evidence shows that senescent cells may
promote oncogenesis through secretion of secretory factors
(SASP)38 and several reports describe abilities of senescent human
fibroblasts to promote growth and tumorigenesis.39 In support of
this, here, we demonstrated that miR-222 overexpression in NFs
induces a SASP phenotype, leading to increased secretion of at
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Fig. 6 MiR-222 and LBR control the ability of breast fibroblasts to activate EMT in breast cancer cells. Immortalised breast NFs were transfected
with miR-222 mimic or siRNA targeting LBR (siLBR) or appropriate controls (NC), and immortalised breast CAFs were transfected with miR-222
inhibitor (i) or to overexpress LBR (LBR OE) or with appropriate controls (NC, pCDNA). Conditioned medium (CM) was collected from fibroblast
cultures and used to treat breast epithelial cancer lines MDA-MB-231 or MDA-MB-157. Expression levels of the EMT-associated genes slug and
vimentin were assessed in MDA-MB-231 or MDA-MB-157 cell lines cultured with the conditioned medium (CM) from the transfected
fibroblasts as labelled using qPCR (a, c) or western blots (b, d). qPCR data represent biological triplicates, while β-actin represents a loading
control for the western analysis. ***p < 0.0005, **p < 0.005, *p < 0.05
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In conclusion, we present miR-222 and LBR as key molecules
involved in transformation and maintenance of breast CAFs, which
in turn therefore impacts on the aggressive tumorigenic behaviour
of breast cancer cells. These molecules are novel targets for
therapeutic intervention.
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